中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

44 records (took 0.036 seconds)

    Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
    12.
    发明授权
    Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds 有权
    六氢吡喃并[3,4-d] [1,3]噻嗪-2-胺化合物

    公开(公告)号：US09045498B2

    公开(公告)日：2015-06-02

    申请号：US14325409

    申请日：2014-07-08

    Applicant: Pfizer Inc.

    Inventor： Michael Aaron Brodney ,  Elizabeth Mary Beck ,  Christopher Ryan Butler ,  Jennifer Elizabeth Davoren ,  Brian Thomas O'Neill

    IPC: C07D513/04 ,  A61K31/542

    CPC classification number: A61K31/542 ,  C07D513/04

    Abstract: The present invention provides compounds of Formula I, and the tautomers thereof, and the pharmaceutically acceptable salts of the compounds and tautomers, wherein the compounds have the structure wherein the variables R1, R2, R3, R4 and x are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

    Abstract translation: 本发明提供式I化合物及其互变异构体，以及化合物和互变异构体的药学上可接受的盐，其中化合物具有其中变量R1，R2，R3，R4和x如说明书中所定义的结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。

    HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
    14.
    发明申请
    HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS 有权
    四氢呋喃并[3,4-d] [1,3]噻嗪-2-胺化合物

    公开(公告)号：US20140163015A1

    公开(公告)日：2014-06-12

    申请号：US14101462

    申请日：2013-12-10

    Applicant: Pfizer Inc.

    Inventor： Michael Aaron Brodney ,  Elizabeth Mary Beck ,  Christopher Ryan Butler ,  Jennifer Elizabeth Davoren ,  Brian Thomas O'Neill

    IPC: C07D513/04

    CPC classification number: A61K31/542 ,  C07D513/04

    Abstract: The present invention provides compounds of Formula I, and the tautomers thereof, and the pharmaceutically acceptable salts of the compounds and tautomers, wherein the compounds have the structure wherein the variables R1, R2, R3, R4 and x are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

    Abstract translation: 本发明提供式I化合物及其互变异构体，以及化合物和互变异构体的药学上可接受的盐，其中化合物具有其中变量R1，R2，R3，R4和x如说明书中所定义的结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。

    Heteroaromatic compounds and their use as dopamine D1 ligands
    18.
    发明授权
    Heteroaromatic compounds and their use as dopamine D1 ligands 有权
    杂芳族化合物及其作为多巴胺D1配体的用途

    公开(公告)号：US09527831B2

    公开(公告)日：2016-12-27

    申请号：US14311963

    申请日：2014-06-23

    Applicant: PFIZER INC.

    Inventor： Michael Aaron Brodney ,  Jennifer Elizabeth Davoren ,  Amy Beth Dounay ,  Ivan Viktorovich Efremov ,  David Lawrence Firman Gray ,  Michael Eric Green ,  Jaclyn Louise Henderson ,  Chewah Lee ,  Scot Richard Mente ,  Steven Victor O'Neil ,  Bruce Nelsen Rogers ,  Lei Zhang

    IPC: C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  A61K31/444 ,  A61K31/506 ,  A61K31/501 ,  A61K31/513

    CPC classification number: C07D401/14 ,  A61K31/444 ,  A61K31/501 ,  A61K31/506 ,  A61K31/513 ,  C07D401/12 ,  C07D403/12 ,  C07D405/14

    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), age-related cognitive decline, dementia, and Parkinson's disease.

    Abstract translation: 及其药学上可接受的盐; 制备过程; 中间体用于制备; 和含有这些化合物或盐的组合物及其用于治疗D1介导的（或D1相关）疾病的用途，包括例如精神分裂症（例如，其认知和负面症状），认知障碍（例如，与精神分裂症相关的认知障碍，AD ，PD或药物治疗），ADHD，冲动性，强迫性赌博，暴饮暴食，孤独症谱系障碍，MCl，年龄相关认知衰退，痴呆，RLS，帕金森病，亨廷顿舞蹈症，焦虑症，抑郁症，MDD，TRD，双相情感障碍， 慢性冷漠，慢性疲劳，创伤后应激障碍，季节性情绪障碍，社会焦虑症，产后抑郁症，血清素综合征，药物滥用和毒品依赖，药物滥用复发，Tourette综合征，迟发性运动障碍，嗜睡，白天过度 嗜睡，恶病质，注意力不集中，性功能障碍，偏头痛，SLE，高血糖症，动脉粥样硬化，血脂异常，肥胖，糖尿病，败血症，缺血后小管 坏死，肾衰竭，低钠血症，抗性水肿，发作性睡病，高血压，充血性心力衰竭，术后眼睛低血压，睡眠障碍和疼痛。

    Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
    19.
    发明授权
    Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds 有权
    烷基取代的六氢吡喃并[3,4-d] [1,3]噻嗪-2-胺化合物

    公开(公告)号：US09260455B2

    公开(公告)日：2016-02-16

    申请号：US14429215

    申请日：2013-09-09

    Applicant: Pfizer Inc.

    Inventor： Michael Aaron Brodney ,  Elizabeth Mary Beck ,  Christopher Ryan Butler ,  Jennifer Elizabeth Davoren

    IPC: C07D513/04

    CPC classification number: C07D513/04

    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I, wherein the variables R1 and R2 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

    Abstract translation: 公开了化合物的化合物，互变异构体和药学上可接受的盐，其中化合物具有式I的结构，其中变量R1和R2如说明书中所定义。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。

    Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds
    20.
    发明申请
    Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds 审中-公开
    六氢吡喃并[3,4-d] [1,3]噻嗪-2-胺化合物

    公开(公告)号：US20150231144A1

    公开(公告)日：2015-08-20

    申请号：US14695920

    申请日：2015-04-24

    Applicant: Pfizer Inc.

    Inventor： Michael Aaron Brodney ,  Elizabeth Mary Beck ,  Christopher Ryan Butler ,  Jennifer Elizabeth Davoren ,  Brian Thomas O'Neill

    IPC: A61K31/542

    CPC classification number: A61K31/542 ,  C07D513/04

    Abstract: The present invention provides compounds of Formula I, and the tautomers thereof, and the pharmaceutically acceptable salts of the compounds and tautomers, wherein the compounds have the structure wherein the variables R1, R2, R3, R4 and x are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

    Abstract translation: 本发明提供式I化合物及其互变异构体，以及化合物和互变异构体的药学上可接受的盐，其中化合物具有其中变量R1，R2，R3，R4和x如说明书中所定义的结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。

Patent Agency Ranking